Current Report Filing (8-k)
June 17 2022 - 5:08PM
Edgar (US Regulatory)
0000855654
false
0000855654
2022-06-15
2022-06-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): June 15, 2022
ImmunoGen, Inc.
(Exact name of registrant as specified in
its charter)
|
|
|
|
|
|
Massachusetts |
0-17999 |
04-2726691 |
|
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
830 Winter Street, Waltham, MA 02451
(Address of principal executive offices) (Zip
Code)
Registrant's telephone number, including
area code: (781) 895-0600
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
|
Trading Symbol |
|
Name of Each Exchange on Which
Registered |
Common Stock, $.01 par value |
|
IMGN |
|
Nasdaq Global Select Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 - Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
At the 2022 annual meeting of shareholders of ImmunoGen, Inc.
(the “Company”) held on June 15, 2022 (the “2022 Annual Meeting”), shareholders approved an amendment to
our Amended and Restated 2018 Employee, Director and Consultant Equity Incentive Plan (the “Equity Incentive Plan”) to increase
the number of shares authorized for issuance thereunder by 13,000,000. The Board of Directors of the Company approved the amendment to
Equity Incentive Plan on April 1, 2022, subject to shareholder approval.
A summary description of the terms of the Equity Incentive Plan is
set forth in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 26,
2022 (the “Proxy Statement”) under the section of the Proxy Statement entitled “Amendment to our 2018 Employee, Director
and Consultant Equity Incentive Plan to Increase the Number of Shares Authorized for Issuance Thereunder by 13,000,000 (Proposal 4)”
which is qualified by the full text of the Equity Incentive Plan, a copy of which is attached hereto as Exhibit 10.1 and incorporated
herein by reference.
Item 5.07 - Submission of Matters to a Vote of Security Holders.
At the 2022 Annual Meeting, shareholders fixed the number of Directors
constituting the full Board of Directors of the Company at nine as follows:
For: |
|
156,458,503 |
Against: |
|
602,410 |
|
Abstain: |
|
970,421 |
|
Broker Non-Votes: |
|
25,775,973 |
|
At the 2022 Annual Meeting, shareholders elected nine Directors as
follows:
|
|
FOR |
|
|
WITHHELD |
|
|
BROKER NON-VOTES |
|
Stuart A. Arbuckle |
|
153,948,650 |
|
|
4,082,684 |
|
|
25,775,973 |
|
Mark J. Enyedy |
|
155,066,915 |
|
|
2,964,419 |
|
|
25,775,973 |
|
Mark Goldberg, MD |
|
104,686,106 |
|
|
53,345,228 |
|
|
25,775,973 |
|
Tracey L. McCain, Esq. |
|
153,314,079 |
|
|
4,717,255 |
|
|
25,775,973 |
|
Stephen C. McCluski |
|
154,945,808 |
|
|
3,085,526 |
|
|
25,775,973 |
|
Dean J. Mitchell |
|
104,724,631 |
|
|
53,306,703 |
|
|
25,775,973 |
|
Kristine Peterson |
|
105,000,623 |
|
|
53,030,711 |
|
|
25,775,973 |
|
Helen M. Thackray, M.D. |
|
156,597,980 |
|
|
1,433,354 |
|
|
25,775,973 |
|
Richard J. Wallace |
|
154,720,595 |
|
|
3,310,739 |
|
|
25,775,973 |
|
At the 2022 Annual Meeting, shareholders voted to approve an amendment
to our Restated Articles of Organization (the “Amendment”) to increase the number of authorized shares of our common
stock from 300,000,000 to 600,000,000 as follows:
For: |
|
177,336,256 |
Against: |
|
5,516,937 |
|
Abstain: |
|
954,114 |
|
Broker Non-Votes: |
|
0 |
|
At the 2022 Annual Meeting, shareholders voted to approve the amendment
to the Equity Incentive Plan to increase the number of shares authorized for issuance thereunder by 13,000,000 as follows:
For: |
|
138,996,544 |
|
Against: |
|
17,993,078 |
|
Abstain: |
|
1,041,712 |
|
Broker Non-Votes: |
|
25,775,973 |
|
At the 2022 Annual Meeting, shareholders voted, on an advisory basis,
to approve the compensation paid to our named executive officers, as described in the Proxy Statement (referred to as the “say-on-pay
vote”) as follows:
For: |
|
154,412,592 |
|
Against: |
|
2,163,585 |
|
Abstain: |
|
1,455,157 |
|
Broker Non-Votes: |
|
25,775,973 |
|
At the 2022 Annual Meeting, shareholders ratified the appointment of
Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31,
2022 as follows:
For: |
|
179,042,753 |
|
Against: |
|
3,897,306 |
|
Abstain: |
|
867,248 |
|
Broker Non-Votes: |
|
0 |
|
Item 9.01 - Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ImmunoGen, Inc. |
|
(Registrant) |
|
|
|
Date: June 17, 2022 |
By: |
/s/ Renee Lentini |
|
|
Renee Lentini |
|
|
Vice President, Chief Accounting Officer |
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2024 to Aug 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2023 to Aug 2024